Analyst Kostas Biliouris of BMO Capital maintained a Buy rating on Centessa Pharmaceuticals, retaining the price target of $35.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Kostas Biliouris has given his Buy rating due to a combination of factors related to Centessa Pharmaceuticals’ promising position in the orexin agonist market. The company’s lead candidate, ORX750, has shown strong safety and efficacy in human volunteer studies, which positions it well for further development. The potential for CNTA to leverage improvements in efficacy, especially if ALKS’ data shows room for enhancement, adds to the positive outlook.
Moreover, the absence of visual adverse effects in CNTA’s trials, compared to those observed in other companies’ trials, enhances its safety profile. This distinction could prove advantageous if ALKS’ upcoming data also shows a lack of such adverse effects, which would be perceived positively for both companies. Overall, the large and growing orexin agonist market presents ample opportunity for CNTA to establish a strong foothold, potentially becoming a leader in the NT2/IH segment.
Biliouris covers the Healthcare sector, focusing on stocks such as Legend Biotech, Sarepta Therapeutics, and Verve Therapeutics. According to TipRanks, Biliouris has an average return of -10.2% and a 35.22% success rate on recommended stocks.